JP2017537896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537896A5 JP2017537896A5 JP2017525022A JP2017525022A JP2017537896A5 JP 2017537896 A5 JP2017537896 A5 JP 2017537896A5 JP 2017525022 A JP2017525022 A JP 2017525022A JP 2017525022 A JP2017525022 A JP 2017525022A JP 2017537896 A5 JP2017537896 A5 JP 2017537896A5
- Authority
- JP
- Japan
- Prior art keywords
- hvr
- amino acid
- seq
- acid sequence
- region polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 83
- 229920001184 polypeptide Polymers 0.000 claims 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 230000035772 mutation Effects 0.000 claims 17
- 235000001014 amino acid Nutrition 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 3
- 102000058223 human VEGFA Human genes 0.000 claims 3
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 2
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 208000014245 Ocular vascular disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192517 | 2014-11-10 | ||
| EP14192517.2 | 2014-11-10 | ||
| PCT/EP2015/075879 WO2016075037A1 (en) | 2014-11-10 | 2015-11-06 | Bispecific antibodies and methods of use in ophthalmology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537896A JP2017537896A (ja) | 2017-12-21 |
| JP2017537896A5 true JP2017537896A5 (Direct) | 2018-12-06 |
Family
ID=51868112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525022A Pending JP2017537896A (ja) | 2014-11-10 | 2015-11-06 | 二重特異性抗体及び眼科に使用する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10730938B2 (Direct) |
| EP (1) | EP3218399A1 (Direct) |
| JP (1) | JP2017537896A (Direct) |
| KR (1) | KR20170080584A (Direct) |
| CN (1) | CN107074941A (Direct) |
| AR (1) | AR102592A1 (Direct) |
| AU (1) | AU2015345323A1 (Direct) |
| BR (1) | BR112017009764A2 (Direct) |
| CA (1) | CA2963175A1 (Direct) |
| IL (1) | IL251128A0 (Direct) |
| MX (1) | MX2017005977A (Direct) |
| RU (1) | RU2017120360A (Direct) |
| SG (1) | SG11201703428SA (Direct) |
| TW (1) | TW201632551A (Direct) |
| WO (1) | WO2016075037A1 (Direct) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20170081253A (ko) | 2014-11-10 | 2017-07-11 | 에프. 호프만-라 로슈 아게 | 항-il-1베타 항체 및 이의 사용 방법 |
| KR20170082520A (ko) | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-pdgf-b 항체 및 이의 사용 방법 |
| MX2017005642A (es) * | 2014-11-10 | 2017-07-24 | Hoffmann La Roche | Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso. |
| CA2963175A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
| NZ744185A (en) | 2015-12-30 | 2025-09-26 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| US10836819B2 (en) | 2016-08-23 | 2020-11-17 | Medimmune Limited | Anti-VEGF-A and anti-ANG2 antibodies and uses thereof |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CN110818793A (zh) | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| US11130804B2 (en) * | 2018-12-21 | 2021-09-28 | Hoffmann-La Roche Inc. | Antibody that binds to VEGF and IL-1beta and methods of use |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4126940A1 (en) * | 2020-03-30 | 2023-02-08 | F. Hoffmann-La Roche AG | Antibody that binds to vegf and pdgf-b and methods of use |
| CN117500828A (zh) * | 2021-06-04 | 2024-02-02 | 信达生物制药(苏州)有限公司 | 结合VEGF和Ang2的双特异性结合分子以及其用途 |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025211874A1 (ko) * | 2024-04-04 | 2025-10-09 | 주식회사 크로스포인트테라퓨틱스 | 인간 항체 fc 변이체 포함 이중항체 및 그 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| EP1481010A2 (en) | 2002-02-28 | 2004-12-01 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| ES2567198T3 (es) | 2003-01-24 | 2016-04-20 | Applied Molecular Evolution, Inc. | Antagonistas de la IL-1 beta humana |
| DK1587830T3 (da) | 2003-01-28 | 2009-10-26 | Academisch Ziekenhuis Leiden | Peptidinhibitorer af toksiner stammende fra LL-37 |
| US20050226863A1 (en) | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| CN105085678B (zh) | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CN101861168B (zh) | 2007-05-07 | 2014-07-02 | 米迪缪尼有限公司 | 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| PL2293816T3 (pl) | 2008-06-06 | 2013-04-30 | Xoma Us Llc | Sposoby leczenia reumatoidalnego zapalenia stawów |
| RU2368359C1 (ru) | 2008-07-22 | 2009-09-27 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ лечения возрастной макулярной дегенерации |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| EP2391652A4 (en) | 2009-01-29 | 2013-01-02 | Abbott Lab | IL-1 BINDING PROTEINS |
| BR112012007365A2 (pt) | 2009-10-15 | 2016-11-22 | Abbott Lab | proteínas de ligação à il-1 |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| EA201201526A1 (ru) * | 2010-05-07 | 2013-06-28 | Ксома Текнолоджи Лтд. | Способы лечения состояний, связанных с il-1b |
| WO2012021773A1 (en) | 2010-08-13 | 2012-02-16 | Genentech, Inc. | Antibodies to il-1beta and il-18, for treatment of disease |
| CN103328511B (zh) | 2010-09-10 | 2016-01-20 | 埃派斯进有限公司 | 抗-IL-1β抗体及其使用方法 |
| MY163368A (en) | 2010-12-21 | 2017-09-15 | Abbvie Inc | Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| JP5972915B2 (ja) | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Ｆｃ変異体 |
| US9151761B2 (en) | 2011-06-29 | 2015-10-06 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
| MX2014015825A (es) * | 2012-06-28 | 2015-08-10 | Molecular Partners Ag | Proteinas de repeticion de anquirina diseñadas que se unen al factor de crecimiento derivado de plaquetas. |
| RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| CA2883807A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| JP2015532273A (ja) | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ剤を含む薬学的組み合わせ |
| ES3023054T3 (en) | 2012-11-08 | 2025-05-29 | Clearside Biomedical Inc | Methods for the treatment of ocular disease in human subjects |
| BR112015010722A2 (pt) * | 2012-11-09 | 2017-08-22 | Pfizer | Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| AU2014261630B2 (en) * | 2013-04-29 | 2019-05-09 | F. Hoffmann-La Roche Ag | Human FcRn-binding modified antibodies and methods of use |
| SG11201604594SA (en) | 2013-12-20 | 2016-07-28 | Hoffmann La Roche | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
| EP3094647A1 (en) | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| CA2963175A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| KR20170082520A (ko) | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-pdgf-b 항체 및 이의 사용 방법 |
| KR20170081253A (ko) | 2014-11-10 | 2017-07-11 | 에프. 호프만-라 로슈 아게 | 항-il-1베타 항체 및 이의 사용 방법 |
| MX2017005642A (es) | 2014-11-10 | 2017-07-24 | Hoffmann La Roche | Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso. |
| US20190004048A1 (en) | 2015-06-26 | 2019-01-03 | Amgen Inc. | Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor |
| WO2018220169A1 (en) | 2017-06-02 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
-
2015
- 2015-11-06 CA CA2963175A patent/CA2963175A1/en not_active Abandoned
- 2015-11-06 AU AU2015345323A patent/AU2015345323A1/en not_active Abandoned
- 2015-11-06 BR BR112017009764A patent/BR112017009764A2/pt not_active Application Discontinuation
- 2015-11-06 KR KR1020177011694A patent/KR20170080584A/ko not_active Withdrawn
- 2015-11-06 SG SG11201703428SA patent/SG11201703428SA/en unknown
- 2015-11-06 WO PCT/EP2015/075879 patent/WO2016075037A1/en not_active Ceased
- 2015-11-06 RU RU2017120360A patent/RU2017120360A/ru not_active Application Discontinuation
- 2015-11-06 EP EP15790946.6A patent/EP3218399A1/en not_active Withdrawn
- 2015-11-06 MX MX2017005977A patent/MX2017005977A/es unknown
- 2015-11-06 CN CN201580060833.XA patent/CN107074941A/zh active Pending
- 2015-11-06 JP JP2017525022A patent/JP2017537896A/ja active Pending
- 2015-11-09 TW TW104136909A patent/TW201632551A/zh unknown
- 2015-11-09 AR ARP150103645A patent/AR102592A1/es unknown
-
2017
- 2017-03-13 IL IL251128A patent/IL251128A0/en unknown
- 2017-05-09 US US15/590,176 patent/US10730938B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537896A5 (Direct) | ||
| RU2017120360A (ru) | Биспецифические антитела и способы их применения в офтальмологии | |
| JP2017534646A5 (Direct) | ||
| JP2017504566A5 (Direct) | ||
| JP2020062036A5 (Direct) | ||
| JP2017534645A5 (Direct) | ||
| HRP20211357T1 (hr) | Bispecifična protutijela specifična za pd-1 i tim3 | |
| JP2017534644A5 (Direct) | ||
| HRP20200384T1 (hr) | Humanizirana anti-tau(ps422) protutijela i načini uporabe | |
| RU2019134338A (ru) | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 | |
| JP2018537966A5 (Direct) | ||
| HRP20241775T1 (hr) | Bispecifična protutijela koja se specifično vežu na pd1 i lag3 | |
| JP2019501883A5 (Direct) | ||
| IL302486A (en) | Antibodies against the transnephrine receptor with adapted affinity | |
| HRP20211528T1 (hr) | Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije | |
| JP2018522541A5 (Direct) | ||
| JP2019533441A5 (Direct) | ||
| FI3177643T5 (fi) | T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä | |
| HRP20191766T1 (hr) | Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene | |
| HRP20191584T1 (hr) | Anti-cd79b protutijela i načini uporabe | |
| RU2016133347A (ru) | Варианты fc-области с улучшенной способностью связываться с белком а | |
| JP2019502712A5 (Direct) | ||
| RU2016124325A (ru) | Антитела к альфа-синуклеину и способы применения | |
| RU2016133345A (ru) | Варианты fc-области с модифицированными способностями связываться с fcrn | |
| RU2016133346A (ru) | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |